Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.57
-0.23 (-2.35%)
At close: Feb 21, 2025, 4:00 PM
9.70
+0.13 (1.36%)
After-hours: Feb 21, 2025, 4:11 PM EST
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $2.38M in the quarter ending September 30, 2024, a decrease of -9.81%. This brings the company's revenue in the last twelve months to $78.62M, down -33.82% year-over-year. In the year 2023, Vir Biotechnology had annual revenue of $86.18M, down -94.67%.
Revenue (ttm)
$78.62M
Revenue Growth
-33.82%
P/S Ratio
16.52
Revenue / Employee
$133,932
Employees
587
Market Cap
1.32B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VIR News
- 2 days ago - Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference - Business Wire
- 9 days ago - Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
- 5 weeks ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 6 weeks ago - Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why - Benzinga
- 6 weeks ago - Vir Biotechnology: A Rocket Off Phase 1 Data - Seeking Alpha
- 6 weeks ago - Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why - Benzinga
- 6 weeks ago - Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC - Business Wire
- 2 months ago - Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire